MIMETOGEN PHARMACEUTICALS ENTERS INTO LICENSING AGREEMENT WITH ALLERGAN
05 Nov 2015
Aligo is pleased to highlight the signature of an agreement between Mimetogen and Allergan. MSBi Valorisation, now an integral part of Aligo, helped fuel Mimetogen’s success, through the financing and guidance services provided at the early stage of the company’s development. The benefits generated for MSBi Valorisation, Aligo and McGill University are significant and the results demonstrate the relevance of MSBiV / Aligo business model. We congratulate Mr. Garth Cumberlidge, Mimetogen’s CEO and his team, as well as Dr. Uri Saragovi, the principal researcher whose work led to the discovery of the product developed by Mimetogen, for their accomplishments.